Enpro (NPO) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
16 Jan, 2026Executive summary
Q3 2024 sales rose 4.1% to $260.9M, with Sealing Technologies delivering strong profitability and offsetting softness in Advanced Surface Technologies and commercial vehicle OEMs.
Adjusted EBITDA grew 11.1% to $64.1M, and adjusted diluted EPS increased 10.1% to $1.74, driven by favorable mix, pricing, and the AMI acquisition.
Aftermarket/recurring revenue solutions comprised 54% of YTD revenue, providing portfolio stability.
The company is adjusting its 2024 outlook downward due to persistent semiconductor and commercial vehicle OEM demand headwinds.
Acquisition of Advanced Micro Instruments (AMI) for $209.4M in January 2024 expanded Sealing Technologies.
Financial highlights
Q3 Adjusted EBITDA was $64.1M (up 11% year-over-year); adjusted diluted EPS was $1.74 (up 10%).
Free cash flow for the nine months ended September 30, 2024, was $82.8M, down from $133.8M the prior year due to working capital timing and higher cash taxes.
CapEx forecast for 2024 reduced to ~$40M from $60M.
Net leverage ratio at quarter-end was 1.8x trailing 12-month adjusted EBITDA; $468M net debt, $207M cash, $644M total debt.
Quarterly dividend of $0.30/share paid, totaling $19M YTD; $50M share repurchase authorization renewed.
Outlook and guidance
2024 sales now expected to be down low single digits year-over-year, versus prior guidance of flat.
Adjusted EBITDA guidance lowered to $250M–$255M (from $260M–$270M); adjusted EPS to $6.75–$7.00 (from $7.00–$7.60).
Free cash flow for 2024 expected to exceed $110M.
CapEx for 2024 forecast at ~$40M.
Sealing Technologies expected to remain resilient but with seasonally low Q4 results; AST segment profitability expected to decline in Q4 due to soft demand and accelerated growth spending.
Latest events from Enpro
- Strong 2025 results and 2026 growth outlook driven by high-margin tech focus and strategic acquisitions.NPO
Investor presentation18 Feb 2026 - Strong 2025 growth and margin expansion set the stage for robust 2026 performance.NPO
Q4 202518 Feb 2026 - Adjusted EBITDA rose 14% to $74.0M as Sealing Technologies offset semiconductor weakness.NPO
Q2 20242 Feb 2026 - Portfolio transformation and operational excellence drive strong margins and growth outlook.NPO
Sidoti Small-Cap Virtual Investor Conference11 Jan 2026 - Adjusted EBITDA rose 7.1% in 2024, with 2025 guidance signaling further growth.NPO
Q4 202423 Dec 2025 - Accelerating profitable growth with 30%+ margins and strategic expansion in technology sectors.NPO
Gabelli Funds 35th Annual Pump, Valve & Water Symposium23 Dec 2025 - Proxy covers director elections, executive pay, equity plan, auditor, and ESG priorities.NPO
Proxy Filing1 Dec 2025 - Director Adele M. Gulfo joins NewAmsterdam Pharma's board ahead of her re-election vote.NPO
Proxy Filing1 Dec 2025 - Director Ronald C. Keating joins Hayward Holdings' board; biography updated for 2025 vote.NPO
Proxy Filing1 Dec 2025